{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:27:33Z","timestamp":1791638853643,"version":"4.3.4"},"reference-count":89,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AbbVie"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Many patients with spasticity report pain which can be debilitating. Numerous studies have shown onabotulinumtoxinA (onabotA) is efficacious in the management of spasticity but comprehensive data on its impact on spasticity-associated pain is limited. This systematic review aimed to assess the published evidence on the efficacy of onabotA in the management of pain in adults with spasticity. Search strategies were conducted from 1990 to 2023 for journal publications and from 2020 to 2023 for congress proceedings to identify relevant studies on onabotA in adults with spasticity where pain was a reported outcome. Of 665 records identified, 31 unique studies from 33 publications were included (2740 patients). Twenty-seven studies demonstrated a reduction in pain compared to baseline following treatment with onabotA in adults with spasticity (n = 2740). Of these, 12 studies reported a statistically significant reduction in pain with onabotA versus baseline. Sixteen studies reported a clinically meaningful reduction in pain (\u226530% reduction). The reduction in pain with onabotA was consistent across etiologies and a range of pain measures. There was a high level of heterogeneity in the design and quality of the studies identified, which limited statistical analysis; however, the published evidence overall shows a consistent positive trend for the use of onabotA in reducing spasticity-related pain in adults.<\/jats:p>","DOI":"10.3390\/toxins17080418","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T15:34:53Z","timestamp":1755531293000},"page":"418","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["OnabotulinumtoxinA in the Management of Pain in Adult Patients with Spasticity: A Systematic Literature Review"],"prefix":"10.3390","volume":"17","author":[{"given":"Francesca","family":"Bianchi","sequence":"first","affiliation":[{"name":"Neurology and Stroke Unit, Department of Neuroscience, Bufalini Hospital, 47521 Cesena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Nelson","sequence":"additional","affiliation":[{"name":"AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6238-3578","authenticated-orcid":false,"given":"J\u00f6rg","family":"Wissel","sequence":"additional","affiliation":[{"name":"Neurology and Psychosomatic at Wittenbergplatz, University of Potsdam, 14469 Potsdam, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3774-4762","authenticated-orcid":false,"given":"Heakyung","family":"Kim","sequence":"additional","affiliation":[{"name":"UT Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Traut","sequence":"additional","affiliation":[{"name":"AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshini","family":"Shah","sequence":"additional","affiliation":[{"name":"AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Musacchio","sequence":"additional","affiliation":[{"name":"AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahman","family":"Jabbari","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale University, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/0140-6736(90)90389-M","article-title":"What is spasticity?","volume":"335","author":"Lance","year":"1990","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/09638280400014576","article-title":"Spasticity: Clinical perceptions, neurological realities and meaningful measurement","volume":"27","author":"Pandyan","year":"2005","journal-title":"Disabil. Rehabil."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1615\/CritRevPhysRehabilMed.2013007945","article-title":"A Review of Spasticity Treatments: Pharmacological and Interventional Approaches","volume":"25","author":"Chang","year":"2013","journal-title":"Crit. Rev. Phys. Rehabil. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.mpmed.2012.06.008","article-title":"Neurological rehabilitation and the management of spasticity","volume":"40","author":"Stevenson","year":"2016","journal-title":"Medicine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1212\/WNL.0b013e3182762448","article-title":"Toward an epidemiology of poststroke spasticity","volume":"80","author":"Wissel","year":"2013","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Klit, H., Finnerup, N.B., Overvad, K., Andersen, G., and Jensen, T.S. (2011). Pain following stroke: A population-based follow-up study. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0027607"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1177\/1352458507085551","article-title":"Lifetime and actual prevalence of pain and headache in multiple sclerosis","volume":"14","author":"Colombo","year":"2008","journal-title":"Mult. Scler. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1017\/cjn.2015.321","article-title":"Relationship Between Botulinum Toxin, Spasticity, and Pain: A Survey of Patient Perception","volume":"43","author":"Shaikh","year":"2016","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0165-0173(02)00207-2","article-title":"Pain and rehabilitation after spinal cord injury: The case of sensory spasticity?","volume":"40","year":"2002","journal-title":"Brain Res. Brain Res. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1469-8749.2012.04371.x","article-title":"Chronic pain, fatigue, and depressive symptoms in adults with spastic bilateral cerebral palsy","volume":"54","author":"Nieuwenhuijsen","year":"2012","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00415-010-5463-1","article-title":"Early development of spasticity following stroke: A prospective, observational trial","volume":"257","author":"Wissel","year":"2010","journal-title":"J. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/09638280110108878","article-title":"The management of pain in spasticity","volume":"24","author":"Ward","year":"2002","journal-title":"Disabil. Rehabil."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"I1","DOI":"10.1007\/s00415-004-1102-z","article-title":"Neurobiological basis for the use of botulinum toxin in pain therapy","volume":"251","author":"Mense","year":"2004","journal-title":"J. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/PHM.0b013e31826ecb02","article-title":"Does Botulinum Toxin Type A Decrease Pain and Lessen Disability in Hemiplegic Survivors of Stroke with Shoulder Pain and Spasticity? A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"91","author":"Marciniak","year":"2012","journal-title":"Am. J. Phys. Med. Rehabil.\/Assoc. Acad. Physiatr."},{"key":"ref_15","first-page":"108","article-title":"Interventional Approaches to Pain and Spasticity Related to Cerebral Palsy","volume":"50","author":"Peck","year":"2020","journal-title":"Psychopharmacol. Bull."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Beard, S., Hunn, A., and Wight, J. (2003). Treatments for spasticity and pain in multiple sclerosis: A systematic review. Health Technol. Assess., 7, 1\u2013111.","DOI":"10.3310\/hta7400"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.7861\/clinmedicine.2-2-128","article-title":"Botulinum toxin in the management of spasticity in adults","volume":"2","author":"Ward","year":"2002","journal-title":"Clin. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1002\/(SICI)1097-4598(1997)6+<208::AID-MUS15>3.0.CO;2-1","article-title":"Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group","volume":"6","author":"Brin","year":"1997","journal-title":"Muscle Nerve Suppl."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.toxicon.2012.11.025","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome","volume":"67","author":"Esquenazi","year":"2013","journal-title":"Toxicon"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e32376","DOI":"10.1097\/MD.0000000000032376","article-title":"Treatment of adult spasticity with Botox (onabotulinumtoxinA): Development, insights, and impact","volume":"102","author":"Esquenazi","year":"2023","journal-title":"Medicine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1468-1331.2006.01444.x","article-title":"Management of spasticity in adults: Practical application of botulinum toxin","volume":"13","author":"Pathak","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1053\/apmr.2003.50121","article-title":"Botulinum toxin type A therapy in chronic pain disorders","volume":"84","author":"Lang","year":"2003","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1111\/j.1526-4610.2011.02071.x","article-title":"OnabotulinumtoxinA for Chronic Migraine","volume":"57","author":"Blumenfeld","year":"2017","journal-title":"Headache"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.disamonth.2016.05.011","article-title":"Botulinum toxin for chronic pain conditions","volume":"62","author":"Kermen","year":"2016","journal-title":"Dis. Mon."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/0333102414527648","article-title":"Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains","volume":"34","author":"Burstein","year":"2014","journal-title":"Cephalalgia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jns.2014.12.030","article-title":"Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE)","volume":"349","author":"Jankovic","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1080\/00207454.2020.1860039","article-title":"Targeting pain in the long-term treatment of cervical dystonia with botulinum toxin A","volume":"132","author":"Marciniec","year":"2022","journal-title":"Int. J. Neurosci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1046\/j.1526-4610.43.7s.3.x","article-title":"Evidence for antinociceptive activity of botulinum toxin type A in pain management","volume":"43","author":"Aoki","year":"2003","journal-title":"Headache"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Matak, I., Bolcskei, K., Bach-Rojecky, L., and Helyes, Z. (2019). Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins, 11.","DOI":"10.3390\/toxins11080459"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e32370","DOI":"10.1097\/MD.0000000000032370","article-title":"Entering the 4th decade of Botox (onabotulinumtoxinA): A narrative review of its development and impact on patients and medicine","volume":"102","author":"Brin","year":"2023","journal-title":"Medicine"},{"key":"ref_31","unstructured":"Electronic Medicines Compendium (2025, August 05). Summary of Product Characteristics, BOTOX 100 Units. Available online: https:\/\/www.medicines.org.uk\/emc\/medicine\/112."},{"key":"ref_32","unstructured":"Electronic Medicines Compendium (2025, August 05). Summary of Product Characteristics, Dysport 300 Units. Available online: https:\/\/www.medicines.org.uk\/emc\/medicine\/870#."},{"key":"ref_33","unstructured":"Electronic Medicines Compendium (2025, August 05). Summary of Product Characteristics, Xeomin 200 Units, Powder for Solution for Injection. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/2162\/smpc."},{"key":"ref_34","unstructured":"Agenzia Italiana dei Farmaco (2025, August 09). Foglio Illustrativo, Tossina Botulinica di Tipo A, Available online: https:\/\/api.aifa.gov.it\/aifa-bdf-eif-be\/1.0.0\/organizzazione\/3732\/farmaci\/34883\/stampati?ts=FI."},{"key":"ref_35","unstructured":"Government of Canada (2025, August 09). New Labelling Information for all Botulinum Toxin Products: Botox\/Botox Cosmetic, Dysport, Xeomin\/Xeomin Cosmetic and Myobloc. Available online: https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2013\/16787a-eng.php?_ga=1.42483045.1158135760.1472153358."},{"key":"ref_36","unstructured":"National Institute for Health and Care Excellence (2025, August 09). BoNT-A for Treating Children and Young People with Spasticity. Available online: https:\/\/www.nice.org.uk\/guidance\/cg145\/resources\/spasticity-in-under-19s-management-pdf-35109572514757."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Brin, M.F., Nelson, M., Ashourian, N., Brideau-Andersen, A., and Maltman, J. (2024). Update on Non-Interchangeability of Botulinum Neurotoxin Products. Toxins, 16.","DOI":"10.3390\/toxins16060266"},{"key":"ref_38","first-page":"e17645","article-title":"Constraint-Induced Movement Therapy Combined with Botulinum Toxin for Post-stroke Spasticity: A Systematic Review and Meta-Analysis","volume":"13","author":"Nasb","year":"2021","journal-title":"Cureus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/16501970500415348","article-title":"Focal spasticity therapy with botulinum toxin: Effects on function, activities of daily living and pain in 100 adult patients","volume":"38","author":"Bergfeldt","year":"2006","journal-title":"J. Rehabil. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.apmr.2003.10.015","article-title":"Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke","volume":"85","author":"Childers","year":"2004","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/jnnp.2007.128371","article-title":"Shoulder pain and external rotation in spastic hemiplegia do not improve by injection of botulinum toxin A into the subscapular muscle","volume":"79","author":"Arwert","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"De Icco, R., Perrotta, A., Berra, E., Allena, M., Alfonsi, E., Tamburin, S., Serrao, M., Sandrini, G., and Tassorelli, C. (2019). OnabotulinumtoxinA Reduces Temporal Pain Processing at Spinal Level in Patients with Lower Limb Spasticity. Toxins, 11.","DOI":"10.3390\/toxins11060359"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Devier, D., Harnar, J., Lopez, L., Brashear, A., and Graham, G. (2017). Rehabilitation plus OnabotulinumtoxinA Improves Motor Function over OnabotulinumtoxinA Alone in Post-Stroke Upper Limb Spasticity: A Single-Blind, Randomized Trial. Toxins, 9.","DOI":"10.3390\/toxins9070216"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/pmrj.12517","article-title":"Long-Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity","volume":"13","author":"Esquenazi","year":"2021","journal-title":"PM R"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/pmrj.12328","article-title":"Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician- and Patient-Reported Satisfaction: Long-Term Observational Results from the ASPIRE Study","volume":"12","author":"Francisco","year":"2020","journal-title":"PM R"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1212\/01.WNL.0000144349.95487.91","article-title":"Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke","volume":"63","author":"Gordon","year":"2004","journal-title":"Neurology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1017\/cjn.2016.262","article-title":"Real-World, Long-Term Quality of Life Following Therapeutic OnabotulinumtoxinA Treatment","volume":"43","author":"Jog","year":"2016","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1185\/03007995.2010.497103","article-title":"Botulinum toxin type A in post-stroke upper limb spasticity","volume":"26","author":"Kaji","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/STROKEAHA.119.027602","article-title":"Effect of additional rehabilitation after botulinum toxin-A on upper limb activity in chronic stroke: The InTENSE trial","volume":"51","author":"Lannin","year":"2020","journal-title":"Stroke"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Lannin, N.A., Ada, L., English, C., Ratcliffe, J., Faux, S., Palit, M., Gonzalez, S., Olver, J., Schneider, E., and Crotty, M. (2022). Long-term effect of additional rehabilitation following botulinum toxin-A on upper limb activity in chronic stroke: The InTENSE randomised trial. BMC Neurol., 22.","DOI":"10.1186\/s12883-022-02672-8"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.apmr.2020.03.025","article-title":"Efficacy and Safety of MT10107 (Coretox) in Poststroke Upper Limb Spasticity Treatment: A Randomized, Double-Blind, Active Drug-Controlled, Multicenter, Phase III Clinical Trial","volume":"101","author":"Lee","year":"2020","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1161\/STROKEAHA.107.484048","article-title":"Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: A randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide","volume":"39","author":"Lim","year":"2008","journal-title":"Stroke"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2340\/16501977-0672","article-title":"Effects of botulinum toxin A in ambulant adults with spastic cerebral palsy: A randomized double-blind placebo controlled-trial","volume":"43","author":"Maanum","year":"2011","journal-title":"J. Rehabil. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s10072-005-0378-9","article-title":"A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot","volume":"26","author":"Mancini","year":"2005","journal-title":"Neurol. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/PHM.0b013e318168ceaf","article-title":"The Use of Botulinum Toxin for Spasticity After Spinal Cord Injury","volume":"87","author":"Marciniak","year":"2008","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00415-004-0297-3","article-title":"Botulinum toxin in post-stroke patients: Stiffness modifications and clinical implications","volume":"251","author":"Miscio","year":"2004","journal-title":"J. Neurol."},{"key":"ref_57","first-page":"47","article-title":"Disability Changes After Treatment of Upper Limb Spasticity with Botulinum Toxin","volume":"10","author":"Reiter","year":"1996","journal-title":"J. Neurol. Rehabil."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1212\/01.WNL.0000080081.74117.E4","article-title":"Botulinum toxin treatment of painful tonic spasms in multiple sclerosis","volume":"61","author":"Restivo","year":"2003","journal-title":"Neurology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/PL00007851","article-title":"Efficacy of botulinum toxin A in upper limb function of hemiplegic patients","volume":"249","author":"Rousseaux","year":"2002","journal-title":"J. Neurol."},{"key":"ref_60","first-page":"25","article-title":"Onabotulinumtoxin-A injection for disabling lower limb flexion in hemiplegic patients","volume":"35","author":"Rousseaux","year":"2014","journal-title":"NeuroRehabilitation"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/026921559701100102","article-title":"Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patients","volume":"11","author":"Sampaio","year":"1997","journal-title":"Clin. Rehabil."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Seo, H.G., Paik, N.J., Lee, S.U., Oh, B.M., Chun, M.H., Kwon, B.S., and Bang, M.S. (2015). Neuronox versus BOTOX in the Treatment of Post-Stroke Upper Limb Spasticity: A Multicenter Randomized Controlled Trial. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128633"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1212\/WNL.46.5.1306","article-title":"Botulinum toxin type A in the treatment of upper extremity spasticity: A randomized, double-blind, placebo-controlled trial","volume":"46","author":"Simpson","year":"1996","journal-title":"Neurology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s10072-005-0379-8","article-title":"Botulinum toxin type A for upper limb spasticity following stroke: An open-label study with individualised, flexible injection regimens","volume":"26","author":"Slawek","year":"2005","journal-title":"Neurol. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/00002060-200210000-00009","article-title":"Local botulinum toxin type A injections in the treatment of spastic toes","volume":"81","author":"Suputtitada","year":"2002","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3233\/BMR-2002-162-301","article-title":"Botulinum toxin A in the treatment of spasticity\u2014An open label study","volume":"16","author":"Turhanoglu","year":"2002","journal-title":"J. Back Musculoskelet. Rehabil."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00002060-200204000-00005","article-title":"Effect of intramuscular botulinum toxin injection on upper limb spasticity in stroke patients","volume":"81","author":"Wang","year":"2002","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0885-3924(00)00146-9","article-title":"Management of spasticity associated pain with botulinum toxin A","volume":"20","author":"Wissel","year":"2000","journal-title":"J. Pain Symptom Manag."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpainsymman.2016.01.007","article-title":"OnabotulinumtoxinA Improves Pain in Patients with Post-Stroke Spasticity: Findings from a Randomized, Double-Blind, Placebo-Controlled Trial","volume":"52","author":"Wissel","year":"2016","journal-title":"J. Pain Symptom Manag."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/02699052.2016.1218545","article-title":"Functional impact of different muscle localization techniques for Botulinum neurotoxin A injections in clinical routine management of post-stroke spasticity","volume":"31","author":"Zeuner","year":"2017","journal-title":"Brain Inj."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0304-3959(01)00371-2","article-title":"What is a \u201cclinically meaningful\u201d reduction in pain?","volume":"94","author":"Rowbotham","year":"2001","journal-title":"Pain"},{"key":"ref_72","unstructured":"Wells, G.A., Shea, B., O\u2019Connell, D., Peterson, J., Welch, V., Losos, M., and Tugwell, P. (2025, August 05). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analyses. Available online: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"256","DOI":"10.23736\/S1973-9087.16.04329-X","article-title":"Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: A systematic review with meta-analysis and trial sequential analysis","volume":"53","author":"Dong","year":"2017","journal-title":"Eur. J. Phys. Rehabil. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.toxicon.2015.07.013","article-title":"Explanation of timing of botulinum neurotoxin effects, onset and duration, and clinical ways of influencing them","volume":"107 Pt A","author":"Hallett","year":"2015","journal-title":"Toxicon"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1001\/jamapsychiatry.2016.3730","article-title":"Leveraging Statistical Methods to Improve Validity and Reproducibility of Research Findings","volume":"74","author":"Blackford","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1080\/10749357.2020.1843845","article-title":"Early clinical predictors of post stroke spasticity","volume":"28","author":"Ri","year":"2021","journal-title":"Top. Stroke Rehabil."},{"key":"ref_77","first-page":"547","article-title":"The Onset and Frequency of Spasticity After First Ever Stroke","volume":"110","author":"Katoozian","year":"2018","journal-title":"J. Natl. Med. Assoc."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.rehab.2018.07.006","article-title":"Association of spasticity and motor dysfunction in chronic stroke","volume":"62","author":"Pundik","year":"2019","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1053\/apmr.2002.35474","article-title":"Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity","volume":"83","author":"Brashear","year":"2002","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1002\/acr.20543","article-title":"Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP)","volume":"63","author":"Hawker","year":"2011","journal-title":"Arthritis Care Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0304-3959(81)90199-8","article-title":"Measurement of pain: Patient preference does not confound pain measurement","volume":"10","author":"Kremer","year":"1981","journal-title":"Pain"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2340\/00015555-1246","article-title":"Assessment of pruritus intensity: Prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus","volume":"92","author":"Phan","year":"2012","journal-title":"Acta Dermato-Venereol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/01.STR.30.7.1357","article-title":"Can stroke patients use visual analogue scales?","volume":"30","author":"Price","year":"1999","journal-title":"Stroke"},{"key":"ref_84","first-page":"543","article-title":"Comparison between the Visual Analog Scale and the Numerical Rating Scale in the perception of esthetics and pain","volume":"15","author":"Rosas","year":"2017","journal-title":"Int. Orthod."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/ard.38.6.560","article-title":"Vertical or horizontal visual analogue scales","volume":"38","author":"Scott","year":"1979","journal-title":"Ann. Rheum. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/pmrj.13195","article-title":"Pain, disability, and quality of life in participants after concurrent onabotulinumtoxinA treatment of upper and lower limb spasticity: Observational results from the ASPIRE study","volume":"16","author":"Bavikatte","year":"2024","journal-title":"PM R"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Ye, D.H., Chun, M.H., Park, Y.G., Paik, N.J., Lee, S.U., Yoo, S.D., and Kim, D.Y. (2023). A Randomized, Double-Blind, Active Control, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Liztox((R)) versus Botox((R)) in Post-Stroke Upper Limb Spasticity. Toxins, 15.","DOI":"10.3390\/toxins15120697"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Cameron, I.D., Ada, L., Crotty, M., Palit, M., Huang, L., Olver, J., Faux, S.G., Gonzales, S., Anthonisz, B., and Bowman, M. (2024). The Lack of Effect of Botulinum Toxin-A on Upper Limb Activity in Chronic Stroke: A Short Report from the InTENSE Trial. Toxins, 16.","DOI":"10.3390\/toxins16120510"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/17\/8\/418\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:30:15Z","timestamp":1760034615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/17\/8\/418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":89,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["toxins17080418"],"URL":"https:\/\/doi.org\/10.3390\/toxins17080418","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]}}}